KremenchutzkyMRiceGPABaskervilleJ. The natural history of multiple sclerosis: A geographically based study 9: Observations on the progressive phase of the disease. Brain2006; 129: 584–594.
2.
HeesenCKasperJSegalJ. Decisional role preferences, risk knowledge and information interests in patients with multiple sclerosis. Mult Scler2004; 10: 643–650.
3.
AmatoMPLangdonDMontalbanX. Treatment of cognitive impairment in multiple sclerosis: Position paper. J Neurol2013; 260: 1452–1468.
4.
KobeltGGiselaKJennyB. Costs and quality of life in multiple sclerosis in Europe: Method of assessment and analysis. Eur J Health Econ2006; 7: 5–13.
5.
FeuilletLReuterFAudoinB. Early cognitive impairment in patients with clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler2007; 13: 124–127.
6.
SchwartzCEQuarantoBRHealyBC. Cognitive reserve and symptom experience in multiple sclerosis: A buffer to disability progression over time?Arch Phys Med Rehabil2013; 94: 1971–1981.e1.
7.
MoriFKusayanagiHNicolettiCG. Cortical plasticity predicts recovery from relapse in multiple sclerosis. Mult Scler2014; 20: 451–457.
8.
WegnerCFilippiMKortewegT. Relating functional changes during hand movement to clinical parameters in patients with multiple sclerosis in a multi-centre fMRI study. Eur J Neurol2008; 15: 113–122.
9.
De StefanoNNarayananSFrancisGS. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol2001; 58: 65–70.
10.
AmatoMPHakikiBGorettiB. Association of MRI metrics and cognitive impairment in radiologically isolated syndromes. Neurology2012; 78: 309–314.
11.
JokubaitisVGSpelmanTKalincikT. Predictors of disability worsening in clinically isolated syndrome. Ann Clin Transl Neurol2015; 2: 479–491.
12.
HeASpelmanTJokubaitisV. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis. JAMA Neurol2015; 72: 405–413.
13.
CohenJAColesAJArnoldDL. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial. Lancet2012; 380: 1819–1828.
14.
GiovannoniGTurnerBGnanapavanS. Is it time to target no evident disease activity (NEDA) in multiple sclerosis?Mult Scler Relat Disord2015; 4: 329–333.
15.
SormaniMPRioJTintorèM. Scoring treatment response in patients with relapsing multiple sclerosis. Mult Scler2013; 19: 605–612.
16.
RíoJCastillóJRoviraA. Measures in the first year of therapy predict the response to interferon β in MS. Mult Scler2009; 15: 848–853.
17.
SormaniMPArnoldDLDe StefanoN. Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann Neurol2014; 75: 43–49.
18.
FelsonDTSmolenJSWellsG. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis2011; 70: 404–413.
19.
BurtRKBalabanovRHanX. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis. JAMA2015; 313: 275–284.
20.
NashRAHuttonGJRackeMK. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): A 3-year interim report. JAMA Neurol2015; 72: 159–169.
21.
GiovannoniGComiGCookS. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med2010; 362: 416–426.
22.
LeistTPComiGCreeBAC. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): A phase 3 randomised trial. Lancet Neurol2014; 13: 257–267.
